Mutations in Cytoplasmic Loops of the KCNQ1 Channel and the Risk of Life-Threatening Events Implications for Mutation-Specific Response to beta-Blocker Therapy in Type 1 Long-QT Syndrome

Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA.
Circulation (Impact Factor: 14.95). 03/2012; 125(16):1988-96. DOI: 10.1161/CIRCULATIONAHA.111.048041
Source: PubMed

ABSTRACT β-Adrenergic stimulation is the main trigger for cardiac events in type 1 long-QT syndrome (LQT1). We evaluated a possible association between ion channel response to β-adrenergic stimulation and clinical response to β-blocker therapy according to mutation location.
The study sample comprised 860 patients with genetically confirmed mutations in the KCNQ1 channel. Patients were categorized into carriers of missense mutations located in the cytoplasmic loops (C loops), membrane-spanning domain, C/N terminus, and nonmissense mutations. There were 27 aborted cardiac arrest and 78 sudden cardiac death events from birth through 40 years of age. After multivariable adjustment for clinical factors, the presence of C-loop mutations was associated with the highest risk for aborted cardiac arrest or sudden cardiac death (hazard ratio versus nonmissense mutations=2.75; 95% confidence interval, 1.29-5.86; P=0.009). β-Blocker therapy was associated with a significantly greater reduction in the risk of aborted cardiac arrest or sudden cardiac death among patients with C-loop mutations than among all other patients (hazard ratio=0.12; 95% confidence interval, 0.02-0.73; P=0.02; and hazard ratio=0.82; 95% confidence interval, 0.31-2.13; P=0.68, respectively; P for interaction=0.04). Cellular expression studies showed that membrane spanning and C-loop mutations produced a similar decrease in current, but only C-loop mutations showed a pronounced reduction in channel activation in response to β-adrenergic stimulation.
Patients with C-loop missense mutations in the KCNQ1 channel exhibit a high risk for life-threatening events and derive a pronounced benefit from treatment with β-blockers. Reduced channel activation after sympathetic activation can explain the increased clinical risk and response to therapy in patients with C-loop mutations.

Download full-text


Available from: Jin O-Uchi, Feb 11, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This past year saw multiple important advances in the field clinical cardiac electrophysiology. Seminal articles describing new anticoagulant drugs for stroke prevention in atrial fibrillation were published. New results that raise questions regarding the safety of dronedarone and several new promising techniques in AF ablation were described. Important articles that refine our understanding of the risk of sudden death among Wolff-Parkinson-White patients were published. In the basic and translational sciences, the application of gene therapy to the study and potential treatment of arrhythmias was described, whereas genetic determinants important to the optimal treatment of inherited arrhythmia syndromes were further elucidated. Issues relevant to cardiac rhythm device therapy included investigations into the St. Jude Riata lead, new applications of device monitoring, predicting response to cardiac resynchronization therapy, and the use of pacemakers for vasovagal syncope.
    Journal of the American College of Cardiology 09/2009; 54(9):777-87. DOI:10.1016/j.jacc.2009.05.031 · 15.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Long QT Syndrome has been the first inherited arrhythmogenic syndrome to be extensively characterized in clinical cardiology: its genetic bases were disclosed in the early nineties by Mark Keating thus opening the field of molecular arrhythmology(1-3). The publication of Keating's work generated a lot of excitement among those involved in the care of LQTS patients as it became clear that the possibility to identify in the clinics the DNA variants that cause LQTS would impact clinical management of families affected by the disease. (SELECT FULL TEXT TO CONTINUE).
    Circulation 03/2012; 125(16):1961-3. DOI:10.1161/CIRCULATIONAHA.112.102293 · 14.95 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: OPINION STATEMENT: The inherited channelopathies are a rare, heterogeneous group of diseases with widely variable clinical presentations and courses. Systematic clinical and experimental work has led to identification of disease-causing genetic mutations and their biophysical manifestation. The process by which the knowledge base is developed, from genetic mutation, to cardiac myocyte, to whole heart, and finally to clinical presentation, has dramatically expanded our understanding of these diseases. Most importantly, we can now begin to comprehend how small changes at the genetic level can dramatically influence a patient's clinical course.
    Current Treatment Options in Cardiovascular Medicine 08/2012; 14(5):473-89. DOI:10.1007/s11936-012-0198-1